Table 2. Characteristics of Sample of Crohn’s Patients by Anti-CBir1 IgG Category.
| Low anti-CBir1 IgG | High anti-CBir1 IgG | P value | |
|---|---|---|---|
| Age, mean (SD) | 45.4 (15.8) | 39.7(14.8) | 0.0692a |
| Sex, N (%) | 0.2871b | ||
| Females | 61 (60.4%) | 24 (70.6%) | |
| Males | 40 (39.6%) | 10 (29.4%) | |
| Race, N (%) | 0.2417c | ||
| Caucasians | 64 (63.4%) | 18 (52.9%) | |
| African Americans | 35 (34.7%) | 14 (41.2%) | |
| Others | 2 (2.0%) | 2 (5.9%) | |
| Duration of disease in years, mean (SD) | 9.7 (11.0) | 9.3 (11.3) | 0.8989d |
| Steroid use, N (%) | 38 (37.6%) | 19 (57.6%) | 0.0441b |
| Tobacco use, N (%) | 22 (21.8%) | 8 (24.2%) | 0.7685b |
| TNF blocker use, N (%) | 65 (64.4%) | 22 (66.7%) | 0.8092b |
| VD use, N (%) | 15 (14.9%) | 5 (15.2%) | 0.9665b |
| UST use, N (%) | 27 (26.7%) | 9 (27.3%) | 0.9515b |
| Thiopurine, N (%) | 13 (12.9%) | 8 (24.2%) | 0.1188b |
| MTX, N (%) | 13 (12.9%) | 3 (9.1%) | 0.5609b |
| Crohn’s behavior, N (%) | 0.5271b | ||
| Penetrating | 37 (36.6%) | 15 (45.5%) | |
| Stricturing | 26 (25.7%) | 9 (27.3%) | |
| None | 38 (37.6%) | 9 (27.3%) | |
| Perianal, N (%) | 31 (30.7%) | 9 (27.3%) | 0.7093b |
| UGI, N (%) | 21 (20.8%) | 9 (27.3%) | 0.4381b |
| Crohn’s location, N (%) | 0.0251b | ||
| Ileal | 17 (16.8%) | 6 (17.6%) | |
| Colonic | 35 (34.7%) | 4 (11.8%) | |
| Ileocolonic | 49 (48.5%) | 23 (67.6%) | |
| BMI, mean (SD) | 27.3 (7.1) | 25.3 (7.7) | 0.1849a |
| Obesity, N (%) | 39 (38.6%) | 9 (27.3%) | 0.2381b |
| PPI use, N (%) | 34 (33.7%) | 8 (24.2%) | 0.3111b |
aTwo sample t-test; bChi-square; cFisher’s exact; dWilcoxon rank sum. SD: standard deviation; TNF: tumor necrosis factor; VD: vedolizumab; UST: ustekinumab; MTX: methotrexate; UGI: upper gastrointestinal; BMI: body mass index; PPI: proton pump inhibitor.